Authors

Latest:

Dr. Gauthier on Potential for CAR T Cells in CLL

Jordan Gauthier, MD, MSc, senior clinical research fellow, Fred Hutchinson Cancer Research Center, discusses the potential for chimeric antigen receptor T-cell therapy in the treatment of chronic lymphocytic leukemia.

Jordan J. Karlitz, MD

Latest:

Despite Benefits, Screening for Lynch Syndrome Often Overlooked

Much work needs to be done to increase Lynch syndrome screening rates and better understand the factors that are associated with low testing rates.

Jordi Bruix, MD

Latest:

Dr. Bruix Discusses Progress of Second-Line Treatment in HCC

Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer at University of Barcelona, discusses the impact of the recent progress in the second-line treatment setting for hepatocellular carcinoma.

Jordi Bruix, MD, Hospital Clinic University of Barcelona

Jordi Giralt, MD, PhD

Latest:

Dr. Giralt on Mucoadhesive Clonidine in Head and Neck Cancer

Jordi Giralt, MD, PhD, pathology, radiology, oncology, University Hospital Vall d'Hebron, discusses a study that examined mucoadhesive clonidine (Clonidine Lauriad) in the prevention of severe radiomucositis in patients with head and neck cancer.

Jorge A. Garcia, MD

Jorge A. Garcia, MD is the current director of the GU Medical Oncology clinical and research programs at University Hospitals Seidman Cancer Center.

Latest:

Dr Garcia on the Safety of Earlier Use of Lu 177 Vipivotide Tetraxetan PSMA+ mCRPC

Jorge A. Garcia, MD, discusses the safety of Lu 177 vipivotide tetraxetan earlier in the treatment course for PSMA–positive mCRPC.

Jorge A. Garcia, MD, FACP, Taussig Cancer Institute

Jorge Cortes, MD

Jorge Cortes, MD, is director of the Georgia Cancer Center at Augusta University.

Latest:

Dr Cortes on the Evolving Treatment Paradigm for Leukemia and Lymphoma

Jorge Cortes, MD, discusses the state of the leukemia and lymphoma treatment paradigms in 2025 in recognition of Leukemia and Lymphoma Awareness Month

Jorge E. Cortes, MD

Latest:

Asciminib Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase in the Pivotal Phase 3 ASC4FIRST Study: Week 96 Update

Dr. Jorge E. Cortes presents updated week 96 results from the Phase 3 ASC4FIRST study, showing that asciminib continues to demonstrate superior efficacy and a more favorable safety profile compared with investigator-selected TKIs in newly diagnosed chronic-phase CML, reinforcing its potential as a standard of care.

Jorge E. Cortes, MD, MD Anderson Cancer Center

Latest:

GIMEMA LAL2116, D-ALBA, Updated Results and Prognostic Impact of IKZF1 in Ph+ ALL

Robin Foà, MD, leads a discussion on the primary takeaways from the GIMEMA LAL2116, D-ALBA trial, particularly the prognostic impact of the IKZF1-plus genotype and the Ikaros mutation.

Jorge E. Cortes, MD, University of Texas MD Anderson Cancer Center

Jorge Garcia, MD

Latest:

Dr. Garcia Discusses the LATITUDE Study in Prostate Cancer

Jorge Garcia, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses the LATITUDE study in prostate cancer.

Jorge J. Castillo, MD

Latest:

New Advances in Waldenström Macroglobulinemia

Understanding Waldenström Macroglobulinemia, and genomic profiles influencing clinical presentation and treatment strategies.

Jorge Moscat, PhD

Latest:

Novel Protein Research May Help Unravel Obesity-Cancer Link

Researchers of Sanford Burnham Prebys Medical Discovery Institute indicates that p62 may represent a link connecting obesity, inflammation, and progression of certain cancers.

Jorge Sierra MD, PhD

Latest:

Dr. Jorge Sierra on Risk Adapted Therapy in AML

Jorges E. Cortes, MD

Latest:

Dr. Cortes on Tyrosine Kinase Inhibitors in CML

Jorge E. Cortes, MD, shares his experience with tyrosine kinase inhibitors as treatment of patients with chronic myeloid leukemia.

Jose Baselga, MD, PhD

Latest:

Dr. Baselga on Biomarker Research for Breast Cancer

José Baselga, MD, PhD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses biomarker research for patients with breast cancer.

Jose Baselga, MD, PhD, Memorial Sloan Kettering Cancer Center

Jose Leis, MD

Latest:

Dr. Leis on Promising Combo Regimens Being Explored in CLL

Jose Leis, MD, associate professor of Medicine, Mayo Clinic, discusses combination regimens that seem promising and are under investigation in the treatment landscape of chronic lymphocytic leukemia.

Jose M. Pacheco, MD

Latest:

Dr. Pacheco on the Mechanism of Action of Trastuzumab Deruxtecan in HER2-Overexpressing Metastatic NSCLC

Jose Pacheco, MD, discusses the mechanism of action of trastuzumab deruxtecan in patients with HER2-overexpressing metastatic non–small cell lung cancer.